Home › Compare › TXHPF vs ABBV
TXHPF yields 44865541.28% · ABBV yields 3.06%● Live data
📍 TXHPF pulled ahead of the other in Year 1
Combined, TXHPF + ABBV cover 0 of 12 months — good coverage
Which stock is actually better after tax? Adjust your rate to find out.
What's the optimal mix of TXHPF + ABBV for your $10,000?
TechnoPro Holdings, Inc., through its subsidiaries, operates as a technology-focused staffing and services company in Japan and internationally. The company offers various services, including engineer staffing, contract assignment, engineering consulting, domestic nearshore and overseas offshore delivery, job placement, and education and training in the machinery, electrics and electronics, embedded controls, information systems, IT infrastructure, software development and maintenance, civil engineering, production plant, architecture, chemistry, biotechnology, and construction areas. It also provides IT system integration and package products; application development and IT consulting services; assessment, inspection, design, and supervision services of buildings; employment services for people with disabilities; and education and training services for CAD, programming, network construction, web design, PC operation, Microsoft office, etc. In addition, the company offers engineering consultancy and offshore development services; and recruitment process outsourcing services, as well as operates as a recruitment agency. TechnoPro Holdings, Inc. was formerly known as Prompt Holdings, Inc. and changed its name to TechnoPro Holdings, Inc. in April 2013. The company was founded in 1995 and is headquartered in Tokyo, Japan.
Full TXHPF Calculator →AbbVie Inc. discovers, develops, manufactures, and sells pharmaceuticals in the worldwide. The company offers HUMIRA, a therapy administered as an injection for autoimmune and intestinal Behçet's diseases; SKYRIZI to treat moderate to severe plaque psoriasis in adults; RINVOQ, a JAK inhibitor for the treatment of moderate to severe active rheumatoid arthritis in adult patients; IMBRUVICA to treat adult patients with chronic lymphocytic leukemia (CLL), small lymphocytic lymphoma (SLL), and VENCLEXTA, a BCL-2 inhibitor used to treat adults with CLL or SLL; and MAVYRET to treat patients with chronic HCV genotype 1-6 infection. It also provides CREON, a pancreatic enzyme therapy for exocrine pancreatic insufficiency; Synthroid used in the treatment of hypothyroidism; Linzess/Constella to treat irritable bowel syndrome with constipation and chronic idiopathic constipation; Lupron for the palliative treatment of advanced prostate cancer, endometriosis and central precocious puberty, and patients with anemia caused by uterine fibroids; and Botox therapeutic. In addition, the company offers ORILISSA, a nonpeptide small molecule gonadotropin-releasing hormone antagonist for women with moderate to severe endometriosis pain; Duopa and Duodopa, a levodopa-carbidopa intestinal gel to treat Parkinson's disease; Lumigan/Ganfort, a bimatoprost ophthalmic solution for the reduction of elevated intraocular pressure (IOP) in patients with open angle glaucoma (OAG) or ocular hypertension; Ubrelvy to treat migraine with or without aura in adults; Alphagan/ Combigan, an alpha-adrenergic receptor agonist for the reduction of IOP in patients with OAG; and Restasis, a calcineurin inhibitor immunosuppressant to increase tear production, as well as other eye care products. AbbVie Inc. has a research collaboration with Dragonfly Therapeutics, Inc. The company was incorporated in 2012 and is headquartered in North Chicago, Illinois.
Full ABBV Calculator →Save your analysis + weekly dividend insights. Free forever.
⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.